Analystreport

Castle Biosciences (NASDAQ: CSTL) had its price target lowered by analysts at Robert W. Baird from $38.00 to $35.00. They now have an "outperform" rating on the stock.

Castle Biosciences, Inc. - Common stock  (CSTL) 
Last castle biosciences, inc. - common stock earnings: 3/10 04:05 pm Check Earnings Report